1Gartel A L, Tyner A L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis [J]. Mol Cancer Ther,2002,1 (8) :639-649.
2Blagosklonny M V. Are p27 and p21 cytoplasmic oncoproteins? [J]. Cell Cycle, 2002,1 (6) :391-393.
3Gartel A L, Radhakrishnan S K. Lost in transcription: p21 repression, mechanisms, and consequences [J].Cancer Res, 2005,65(10):3980- 3985.
4Gartel A L. The conflicting roles of the cdk inhibitor p21 (C1P1/WAF1) in apoptosis [J]. Leuk Res, 2005,29 (11):1237-1238.
5Radhakrishnan S K, Gartel A L. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity [J]. Cancer Res, 2006,66(6) :3264-3270.
6Radhakrishnan S K, Halasi M, Bhat U G, et al, Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells [J]. Oncogene, 2008,27 (5): 694-699.
7Bhat U G, Gartel A L. Differential sensitivity of human colon cancer cell lines to the nucleoside analogs ARC and DRB [J]. Int J Cancer, 2008, 122 (6) : 1426-1429.
8Bhat U G, Zipfel P A, Tyler D S, et al. Novel anticancer compounds induce apoptosis in melanoma cells [J]. Cell Cycle, 2008, In press.
9Ahieri D C. Survivin, cancer networks and pathway-directed drug discovery [J]. Nat Rev Cancer, 2008,8(1):61- 70.
10Mandelin A M 2nd, Pope R M. Myeloid cell leukemia-1 as a therapeutic target [J]. Expert Opin Ther Targets, 2007,11 (3) : 363-373.
